SubHero Banner

Prezcobix ® (darunavir/cobicistat) – Expanded indication

July 31, 2020 - The FDA approved Janssen’s Prezcobix (darunavir/cobicistat), in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV)-1 infection in treatment naïve and treatment-experienced adults and pediatric patients weighing at least 40 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V)

Download PDF